Medulloblastoma, Childhood
3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Y-mAbs TherapeuticsNY - New York
1 program1
177Lu-DTPA-omburtamabPhase 1/2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Y-mAbs Therapeutics177Lu-DTPA-omburtamab
Senhwa BiosciencesCX 4945
Prevail TherapeuticsLY2940680
Clinical Trials (3)
Total enrollment: 23 patients across 3 trials
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
Start: Sep 2021Est. completion: Aug 20222 patients
Phase 1/2Terminated
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
Start: Jul 2019Est. completion: Aug 202521 patients
Phase 1/2Terminated
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
Start: Jul 2013Est. completion: Jul 20160
Phase 1Withdrawn
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.